常山药业(300255.SZ)：上半年净亏损2908.90万元

Core Insights - The company reported a revenue of 492 million yuan for the first half of 2025, representing a year-on-year decline of 13.42% [1] - The net profit attributable to shareholders of the listed company was -29.09 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -30.26 million yuan [1] - The basic earnings per share were -0.03 yuan [1]